

Clin Infect Dis 2006 Apr 1;42(7):e61-5. Epub 2006 Feb 21.
Erratum in: Clin Infect Dis. 2006 Nov 15;43(10):1376.

Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases.

van Burik JA, Hare RS, Solomon HF, Corrado ML, Kontoyiannis DP.

University of Minnesota, Minneapolis, Minnesota, USA.

To evaluate the activity of posaconazole for treatment of zygomycosis, a disease for which therapeutic options are limited, we conducted a retrospective study including 91 patients with zygomycosis (proven zygomycosis, 69 patients; probable zygomycosis, 22 patients). Patients had infection that was refractory to prior antifungal treatment (n=81) or were intolerant of such treatment (n=10) and participated in the compassionate-use posaconazole (800 mg/day) program. The rate of success (i.e., either complete or partial response) at 12 weeks after treatment initiation was 60%, and 21% of patients had stable disease. The overall high success and survival rates reported here provide encouraging data regarding posaconazole as an alternative therapy for zygomycosis.

PMID: 16511748 [PubMed - indexed for MEDLINE]